Cetus Corp European Patent Office allow intend grant company patent pharmaceutical veterinary preparation genetically engineer Interleukin-2 analog. Interleuken-2 immune modulate protein currently undergo clinical trial United States Europe potential treatment various form cancer Cetus said. It allowance step patent process. Following allowance patent publish opposition nine-month period begin interested party opportunity voice objection patent Cetus said. Reuter 